Skip to main content

Table 2 %Change in natriuretic peptides from the baseline to the study endpoint after the 24-week treatment with ARNI or ARB

From: Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction

 

ARNI-continue group (n = 5)

ARB-switch group (n = 6)

p-value

 

%Change

 

%Change

(%Change)

ANP (pg/mL)

 Baseline

611.6 ± 474.6

 

1155.7 ± 592.6

  

 24 weeks

582.4 ± 511.7

− 9.1 ± 35.6

231.6 ± 233.8*

− 76.9 ± 15.9

0.009

BNP (mg/mL)

 Baseline

195.4 ± 141.5

 

524.9 ± 311.1

  

 24 weeks

235.0 ± 207.6

0.6 ± 37.0

293.7 ± 232.8

− 45.8 ± 38.2

0.175

NT-proBNP (pg/mL)

 Baseline

785.8 ± 457.9

 

1185.3 ± 835.6

  

 24 weeks

880.6 ± 619.8

17.3 ± 24.1

1515.2 ± 1213.5

57.9 ± 29.1

0.016

  1. Values are presented as mean ± standard deviation
  2. ARNI angiotensin receptor-neprilysin inhibitor; ARB angiotensin II receptor blocker; ANP A-type natriuretic peptide; BNP B-type natriuretic peptide; NT-proBNP N-terminal pro-B-type natriuretic peptide; %Change percent change
  3. *p < 0.05 versus the baseline value in the same group
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us